pioglitazone has been researched along with Genetic Predisposition in 10 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim: To study the association between the effectiveness of treatment with pioglitazone non-alcoholic fatty liver disease (NAFLD) in patients with obesity and PPARG rs1801282 (Pro12Ala)-polymorphism in Ukrainians." | 8.02 | ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE. ( Koliada, AK; Martynchuk, OA; Melnyk, NH; Rudenko, NN; Shypulin, VP; Tishchenko, VV, 2021) |
| "The aim: To study the association between the effectiveness of treatment with pioglitazone non-alcoholic fatty liver disease (NAFLD) in patients with obesity and PPARG rs1801282 (Pro12Ala)-polymorphism in Ukrainians." | 4.02 | ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE. ( Koliada, AK; Martynchuk, OA; Melnyk, NH; Rudenko, NN; Shypulin, VP; Tishchenko, VV, 2021) |
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| "The pathology of ADPKD is complex and involves the malfunction of different signaling pathways like cAMP, Hedgehog, and MAPK/ERK pathway owing to the mutated product that is polycystin-1 or 2." | 2.66 | Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. ( Saini, AK; Saini, R; Singh, S, 2020) |
| "Treatment with pioglitazone caused an increase in body weight gain in Pemt(-/-) mice that was mainly due to increased adiposity." | 1.43 | Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. ( Armstrong, EA; Gao, X; Jacobs, RL; Kassiri, Z; Lehner, R; Lingrell, S; Quiroga, AD; Takawale, A; van der Veen, JN; Vance, DE; Yager, JY, 2016) |
| "Although modulating disease progression is an attractive target and will alleviate the burden of the most severe stages, this strategy will not reduce the prevalence of the disease itself." | 1.39 | Using genetics to enable studies on the prevention of Alzheimer's disease. ( Brannan, SK; Burke, JR; Burns, DK; Crenshaw, DG; Gottschalk, WK; Grossman, I; Lutz, MW; Roses, AD; Saunders, AM; Welsh-Bohmer, KA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shypulin, VP | 1 |
| Martynchuk, OA | 1 |
| Rudenko, NN | 1 |
| Koliada, AK | 1 |
| Tishchenko, VV | 1 |
| Melnyk, NH | 1 |
| Saini, AK | 1 |
| Saini, R | 1 |
| Singh, S | 1 |
| Spinney, L | 1 |
| van der Veen, JN | 1 |
| Lingrell, S | 1 |
| Gao, X | 1 |
| Quiroga, AD | 1 |
| Takawale, A | 1 |
| Armstrong, EA | 1 |
| Yager, JY | 1 |
| Kassiri, Z | 1 |
| Lehner, R | 1 |
| Vance, DE | 1 |
| Jacobs, RL | 1 |
| Yasui, T | 1 |
| Okada, A | 1 |
| Hamamoto, S | 1 |
| Ando, R | 1 |
| Taguchi, K | 1 |
| Tozawa, K | 1 |
| Kohri, K | 1 |
| Munkhtulga, L | 1 |
| Nagashima, S | 1 |
| Nakayama, K | 1 |
| Utsumi, N | 1 |
| Yanagisawa, Y | 1 |
| Gotoh, T | 1 |
| Omi, T | 1 |
| Kumada, M | 1 |
| Zolzaya, K | 1 |
| Lkhagvasuren, T | 1 |
| Kagawa, Y | 1 |
| Fujiwara, H | 1 |
| Hosoya, Y | 1 |
| Hyodo, M | 1 |
| Horie, H | 1 |
| Kojima, M | 1 |
| Ishibashi, S | 1 |
| Iwamoto, S | 1 |
| Brouwers, MC | 1 |
| de Graaf, J | 1 |
| van Greevenbroek, MM | 1 |
| Schaper, N | 1 |
| Stehouwer, CD | 1 |
| Stalenhoef, AF | 1 |
| Namvaran, F | 1 |
| Rahimi-Moghaddam, P | 1 |
| Azarpira, N | 1 |
| Dabbaghmanesh, MH | 1 |
| Crenshaw, DG | 1 |
| Gottschalk, WK | 1 |
| Lutz, MW | 1 |
| Grossman, I | 1 |
| Saunders, AM | 1 |
| Burke, JR | 1 |
| Welsh-Bohmer, KA | 1 |
| Brannan, SK | 1 |
| Burns, DK | 1 |
| Roses, AD | 1 |
| Nakamura, T | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
3 reviews available for pioglitazone and Genetic Predisposition
| Article | Year |
|---|---|
Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.
Topics: Animals; Biomarkers; Disease Management; Gene Expression Regulation; Genetic Association Studies; Ge | 2020 |
Pathophysiology-based treatment of urolithiasis.
Topics: Animals; Cardiovascular Diseases; Cholesterol, Dietary; Diabetes Mellitus, Type 2; Disease Models, A | 2017 |
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr | 2010 |
7 other studies available for pioglitazone and Genetic Predisposition
| Article | Year |
|---|---|
ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE.
Topics: Genetic Predisposition to Disease; Genotype; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Pio | 2021 |
Alzheimer's disease: The forgetting gene.
Topics: Age of Onset; Alleles; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoprotein E2; Apolipo | 2014 |
Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice.
Topics: Actins; Adipocytes, White; Adipose Tissue, White; Adiposity; Animals; Anti-Infective Agents; Cell Pr | 2016 |
Regulatory SNP in the RBP4 gene modified the expression in adipocytes and associated with BMI.
Topics: Adipocytes; Adult; Alleles; Asian People; Body Mass Index; Cell Line; Cells, Cultured; Chi-Square Di | 2010 |
Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Anthropometry; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Ge | 2012 |
Using genetics to enable studies on the prevention of Alzheimer's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Cognition; Disease Progression; | 2013 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |